Participants
breast invasive ductal carcinoma
DYSFUNCTION, MAY, OTHER CANCER, CERVICAL CANCER, INFECTIOUS DISEASES, PATHOLOGY, DISEASES
In this study, information about the study was given and informed consent was obtained from all the patients who agreed to participate in the study. Forty hospitalized patients with BC between December 2020 and May 2021 were selected as the control group; 40 patients with BC between June 2021 and December 2021 were selected as the intervention group. Patient inclusion criteria: (1) All patients were diagnosed as breast invasive ductal carcinoma by surgical pathology, and received modified radical mastectomy for the first time; (2) Combined with chemotherapy, radiotherapy, targeted drug therapy, endocrine therapy, etc. (3) Normal cognitive function and ability to cooperate with the study; (4) 30 ≤ age ≤ 82 years old; (5) Informed consent was obtained from all patients. Patient exclusion criteria: (1) Patients with severe heart, brain, liver and kidney function diseases; (2) Other cancers such as cervical cancer; (3) Infectious diseases; (4) Limb dysfunction; (5) Mental diseases; (6) Pregnant or lactating women.